The University of Chicago’s Independent Student Newspaper since 1892

Chicago Maroon

The University of Chicago’s Independent Student Newspaper since 1892

Chicago Maroon

The University of Chicago’s Independent Student Newspaper since 1892

Chicago Maroon

U of C flu research may lead to a one-time vaccine

After researchers noticed H1N1’s peculiar resiliency, they began studying the virus and identified five antibodies from it that could lead to a “holy grail” of flu vaccines.

Yearly flu shots could someday be a thing of the past, according to researchers from the University of Chicago and Emory University. Scientists have identified five antibodies that can potentially be effective against future flu viruses, following a study of the 2009 H1N1 virus.

The studies, published in the Journal of Experimental Medicine, found that the antibodies neutralized all flu strains from the past 10 years, including the Spanish and Avian flu.

“These type of antibodies occurred so frequently, it was quite compelling,” said University researcher Dr. Patrick Wilson.

While seasonal flu mainly targets the elderly and the young, the H1N1 attacked young and healthy people, said Emory University researcher Dr. Jens Wrammert. It was this anomaly that prompted the study after the pandemic first broke out.

What the researchers found was that, unlike other antibodies that bind to the head of the hemaggluttinin protein (HA), the five new antibodies from the H1N1 virus bind to the stalk of the HA protein. Since the stalk does not mutate like the head, flu vaccines would not require yearly updating.

Stalk-binding antibodies have always been in the body, but they were thought to be very rare. The H1N1 virus was unique in promoting the production of stalk-binding antibodies in the body. Because virus stalks don’t tend to mutate, some of the stalk-binding antibodies can be used to protect against many flu viruses, the doctors found.

The study continues with people who received the H1N1 flu shot, and a drug manufacturing company is currently conducting its own tests regarding these antibodies.

“The main impact here is the promise it holds…to produce a vaccine that gives broader protection,” Wrammert said.

Leave a Comment
Donate to Chicago Maroon
$670
$2000
Contributed
Our Goal

Your donation makes the work of student journalists of University of Chicago possible and allows us to continue serving the UChicago and Hyde Park community.

More to Discover
Donate to Chicago Maroon
$670
$2000
Contributed
Our Goal

Comments (0)

All Chicago Maroon Picks Reader Picks Sort: Newest

Your email address will not be published. Required fields are marked *